Related Experiment Video
Updated: Jun 6, 2025

09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.3K
Enhancing tumor immunity via in vivo cDC1 reprogramming
1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Trends in Immunology
|November 22, 2024
Abstract:
A recent study by Ascic et al. demonstrates that in situ reprogramming of tumor cells into conventional dendritic cell (cDC)-like cells using viral-PIB transcription factors creates an immunogenic tumor microenvironment with T cell recruitment and activation. The study highlights the potential of tumor-specific cancer immunotherapy using in vivo reprogrammed cDCs.

